New standards for MDMA, psilocybin


Manufactured or compounded psychedelics must be up to scratch to ensure consistency of products supplied to Australian patients, says TGA The Department of Health and Aged Care has published two new quality standards—one for MDMA and another for psilocybin—following a public consultation process with interested stakeholders including pharmacists. From 1 July last year, MDMA and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Expert insights on the pharmacological management of overweight and obesity
Next Book Review: Maya’s Pharmacy Adventure